Pharmacokinetics of CRD007 in Patients With Abdominal Aorta Aneurisms.

RSPR Pharma

Status and phase: Completed; Phase 1

Conditions: Abdominal Aortic Aneurisms

Treatments: Drug: CRD007

Study type: Interventional

Funder types: Industry

Identifiers

NCT01723618

Cardoz-005

Details and patient eligibility

About

The purpose of the study is to determine the plasma levels of CRD007 in patients with abdominal aortic aneurysms after the administration of single doses of tablets containing 10, 25 and 40 mg CRD007.

Enrollment: 18 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Infra-renal abdominal aortic aneurysm

Exclusion criteria

• Significant concurrent disease or medical conditions that are deemed to interfere with the pharmacokinetics or the safety of CRD007 conduct of the trial

Trial design

18 participants in 3 patient groups

CRD007 10 mg

Experimental group

Description:

CRD007, 10 mg tablet, single dose

Treatment:

Drug: CRD007

CRD007 25 mg

Experimental group

Description:

CRD007, 25 mg tablet, single dose

Treatment:

Drug: CRD007

CRD007 40 mg

Experimental group

Description:

CRD007, 40 mg tablet, single dose

Treatment:

Drug: CRD007